| HEPATITIS A VACCINE
Classifications: vaccine; Therapeutic: vaccine
Prototype: Hepatitis B vaccine
Pregnancy Category: C
720 EIU/0.5 mL, 1440 EIU/1 mL (Havrix); 25 U/0.5 mL, 50 U/1 mL (Vaqta)
Anti-hepatitis A virus antibody titers following administration of hepatitis A vaccine (inactivated) are comparable to those
observed after natural hepatitis A virus infection.
Antibody levels are 50- to 300-fold higher with inactivated hepatitis A vaccine than with passive immunity with human immune
Active immunization against hepatitis A.
Hypersensitivity to any component in vaccine, pregnancy (category C), children <12 mo.
Severe cardiac disease; coagulopathy; concurrent anticoagulant therapy; vitamin K deficiency; lactation.
Route & Dosage
|Hepatitis A Immunization
Adult: IM 1 mL in deltoid muscle; booster dose (1 mL) at 612 mo after primary dose
Child (118 y): IM 2 doses of 0.5 mL in deltoid muscle given 1 mo apart; booster dose (0.5 mL) at 612 mo after primary doses
- Give only in deltoid for adults and children older than 2 y. DO NOT give IV, SC, or intradermally.
- Use vaccine as packaged without dilution.
- Shake vial and syringe well before withdrawal and injection, respectively. Vaccine should be an opaque white suspension;
discard if it looks otherwise.
- Store at 2°8° C (36°47° F). Discard vaccine if it has been frozen.
Adverse Effects (≥1%)CNS: Headache, fatigue
, fever, malaise, somnolence vertigo, insomnia
, photophobia, convulsions, neuropathy, paresthesia. GI:
Anorexia, nausea, abdominal pain, diarrhea, dysgeusia, vomiting. Skin:
Pruritus, rash, urticaria, erythema multiforme, hyperhidrosis, angioedema
(rare). Other: Soreness at injection site, pain, swelling, redness at injection site,
No clinically significant interactions established.
3 wk. Duration:
13 y with single dose, 510 y with booster.
Assessment & Drug Effects
- Do not administer during a febrile illness.
- Assess for S&S of anaphylaxis and have epinephrine available.
Patient & Family Education
- Note: Injection site soreness is common; most adverse reactions are mild and usually last less than 24 h.
- Get booster injection within 612 mo if risk of exposure is still present.